Trending Up0.1500 (5.4745%)
  • Bid / Lots
    2.7700/ 1
  • Ask / Lots
    4.1000/ 1
  • Open / Previous Close
    2.6700 / 2.7400
  • Day Range
    Low 2.6525
    High 2.9600
  • 52 Week Range
    Low 1.7200
    High 9.8750
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 2.74
09:32 ET3622.67
09:35 ET8002.67
09:37 ET15002.75
09:39 ET24002.7
09:46 ET8002.7626
09:48 ET3002.72
09:57 ET4042.8
10:06 ET40002.7279
10:22 ET1862.79
10:31 ET1002.77
11:54 ET5382.8042
11:57 ET1002.8258
12:21 ET1112.845
12:35 ET10842.92
01:00 ET1002.96
01:20 ET10002.91
01:22 ET5642.86
01:31 ET1002.9
01:47 ET30862.9
01:56 ET30472.9
02:00 ET1002.86
02:03 ET5002.895
02:12 ET1002.88
02:18 ET9002.9
02:30 ET8002.91
02:32 ET9002.92
02:39 ET28702.86
02:43 ET6002.9
02:45 ET1112.89
02:48 ET85382.8
02:52 ET1002.86
02:56 ET1002.86
02:57 ET1002.86
02:59 ET1002.86
03:01 ET1002.86
03:08 ET1002.855
03:14 ET2002.855
03:15 ET1002.82
03:24 ET1002.85
03:28 ET6002.85
03:33 ET1002.9
03:35 ET12012.89
03:37 ET9572.88
03:39 ET22532.89
03:44 ET7002.9
03:55 ET1002.85
03:57 ET5382.88
04:00 ET123422.89
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRLYB
Rallybio Corp
United StatesLBPH
Longboard Pharmaceuticals Inc
United StatesKNTE
Kinnate Biopharma Inc
United StatesDMAC
DiaMedica Therapeutics Inc
United StatesOTLK
Outlook Therapeutics Inc
United StatesCYT
Cyteir Therapeutics Inc
As of 2023-12-10

Company Information

Rallybio Corporation is a clinical-stage biotechnology company. The Company is engaged in identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. It offers a program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare hematological disease that impacts fetuses and newborns. Its pipeline includes RLYB212, RLYB116, RLYB114, RLYB331 and ENPP1 Program. RLYB212 is a subcutaneously administered human monoclonal anti-HPA-1a antibody candidate for the prevention of HPA-1a maternal alloimmunization and the occurrence of FNAIT. Its advanced product candidate, RLYB116, is an inhibitor of complement component 5 (C5) used to treat complement dysregulation, including paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG) and others. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule designed for the treatment of complement-mediated ophthalmic diseases.

Contact Information

234 CHURCH STREET, SUITE 1020NEW HAVEN, CT, United States 06510


Executive Chairman of the Board
Martin Mackay
President, Chief Executive Officer, Director
Stephen Uden
Chief Financial Officer, Treasurer
Jonathan Lieber
Chief Medical Officer
Steven Ryder
Independent Director
Helen Boudreau

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.